Enveric Biosciences (ENVB) AI Stock Analysis

• Market Cap: $2.99M
• Dividend Yield: N/A
• Average Volume (3M): 5.37M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.17
• Revenue Growth: N/A
• EPS Growth: 82.47%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -21.33
• Shares Outstanding: 2,471,656
• 10 Day Avg. Volume: 85,941
• 30 Day Avg. Volume: 5,372,926
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.00
• Price Target Upside: 726.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Enveric Biosciences presents a high-risk investment profile with significant financial struggles, including no revenue generation and persistent losses. The technical analysis shows a bearish trend with the stock trading well below key moving averages, indicating weak market sentiment. The negative P/E ratio and lack of dividends further detract from its valuation appeal. Investors should exercise caution given the company's reliance on external financing to sustain operations.

Enveric Biosciences Business Overview & Revenue Model

Company Description

Enveric Biosciences (ENVB) is a biotechnology company focused on developing innovative treatments for mental health disorders. The company leverages its expertise in neuroscience and psychedelic-inspired molecules to create novel therapeutic solutions aimed at addressing the unmet needs in mental health care. Enveric's pipeline is primarily concentrated on the research and development of treatments for conditions such as anxiety, depression, and post-traumatic stress disorder (PTSD).

How the Company Makes Money

Enveric Biosciences primarily makes money through the development and potential commercialization of its proprietary drug candidates. The company invests heavily in research and development to advance its therapeutic pipeline. Revenue is expected to be generated through licensing agreements, partnerships with pharmaceutical companies, and potential product sales following successful clinical trials and regulatory approvals. As Enveric's drug candidates move closer to market readiness, collaborations with established industry players may provide additional financial support and revenue opportunities.

Enveric Biosciences Financial Statement Overview

Summary

Enveric Biosciences is facing significant financial challenges with no revenue generation, ongoing operational losses, and negative cash flows. While the absence of debt reduces financial risk, the company's continued reliance on financing activities to cover cash flow deficits is unsustainable in the long term.

Income Statement

Enveric Biosciences has not generated any revenue since 2020, and the company's net income remains negative, indicating persistent losses. The consistent negative EBIT and EBITDA margins point to ongoing operational challenges and unprofitability.

Balance Sheet

The company has a moderate level of stockholders' equity relative to its total assets, but the lack of debt provides some financial stability. However, the continuous erosion of equity due to ongoing losses is concerning for long-term sustainability.

Cash Flow

Operating cash flow is consistently negative, reflecting the company's inability to generate cash from operations. This is partially offset by financing activities, but free cash flow remains negative, indicating cash burn issues.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
647.09K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
392.22K	0.00	-408.03K	-435.20K	-681.61K	-120.87K
	EBIT
-8.84M	-9.63M	-16.45M	-27.42M	-64.62M	-5.62M
	EBITDA
-10.40M	-9.25M	-16.85M	-19.63M	-63.97M	-6.30M
	Net Income Common Stockholders
-9.86M	-9.57M	―	-18.47M	-48.98M	-6.39M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
9.56K	2.24M	2.29M	17.72M	17.36M	1.58M
	Total Assets
9.56K	3.08M	4.30M	19.55M	26.72M	4.10M
	Total Debt
0.00	0.00	0.00	63.82K	176.30K	0.00
	Net Debt
-9.56K	-2.24M	-2.29M	-17.66M	-17.18M	-1.58M
	Total Liabilities
35.47K	1.49M	2.34M	4.00M	4.41M	681.25K
	Stockholders Equity
-25.91K	1.59M	1.96M	14.67M	22.31M	3.42M
Cash Flow		Free Cash Flow
-8.17M	-7.73M	-14.10M	-17.73M	-12.32M	-3.93M
	Operating Cash Flow
-8.17M	-7.73M	-14.09M	-17.15M	-11.46M	-3.89M
	Investing Cash Flow
-38.00	0.00	11.67K	-584.16K	2.19M	-44.14K
	Financing Cash Flow
7.02M	7.67M	-1.34M	18.18M	24.90M	―

Enveric Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENVB, the sentiment is Negative. The current price of 1.21 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.96, and below the 200-day MA of 5.66, indicating a bearish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 31.60 is Neutral, neither overbought nor oversold. The STOCH value of 7.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENVB.

Enveric Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.36B	1.14	-49.00%	2.63%	17.14%	1.39%
CMPS	43 Neutral	$185.78M	―	-81.56%	―	―	3.88%
RLMD	42 Neutral	$9.04M	―	-132.33%	―	―	19.21%
CYBN	42 Neutral	$1.97M	―	-58.79%	―	―	51.37%
ATAI	42 Neutral	$259.78M	―	-62.43%	―	-0.90%	-89.51%
MNMD	27 Underperform	$409.25M	―	-68.01%	―	―	26.24%
ENVB	18 Underperform	$2.99M	―	-356.82%	―	―	82.47%

Enveric Biosciences Corporate Events

Enveric Biosciences Prepares Presentation for February 2025

Enveric Biosciences, Inc. announced that it has prepared presentation materials, which management intends to release on its website around February 26, 2025. These materials may be used in future presentations to various stakeholders, including investors and business partners, highlighting the company’s ongoing efforts to engage with its audience and provide updates on its business activities.